Answers are grounded in this paper and cite their sources.
Propranolol is the standard first-line systemic therapy for infantile hemangioma (IH), but its antiangiogenic mechanisms remain incompletely defined. Emerging evidence implicates the apelin-APJ system in IH endothelial biology. APJ is enriched in hemangioma-derived endothelial cells (HemECs), and pharmacological inhibition suppresses proliferation, migration and angiogenic behavior, with genetic experiments supporting an APJ-dependent component. Separately, propranolol reduces APLN transcription in IH-derived models, and circulating apelin declines during treatment. These findings motivate investigation of an indirect link through ligand regulation, but do not establish APJ-dependent mediation of propranolol efficacy. This review distinguishes ligand transcription, ligand abundance, receptor expression and receptor-dependent function, integrating IH observations with mechanistic evidence from other vascular and disease models. We examine endothelial cell states, HIF-1α-dependent transcription, and the distinct SOX18-mevalonate mechanism of R(+)-propranolol. Cross-disease intervention studies provide a rationale for investigating treatment responsiveness. Priorities include defining functional ligand sources and recipient cells, testing receptor-dependent effects on drug response, validating circulating biomarkers, and establishing developmental safety before therapeutic translation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: